Mylan Amlodipine Tablets Recalled for CGMP Deviations
Mylan Institutional, Inc. is recalling Amlodipine Besylate Tablets because they were not manufactured according to Good Manufacturing Practices.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classified this as a Class II recall. Per the rubric, FDA Class II recalls are assigned a severity score of 4 (Severe), particularly when involving structural manufacturing deviations that may impact drug efficacy or safety.
Plain-English summary
Mylan Institutional, Inc. (d.b.a. UDL Laboratories) is recalling Amlodipine Besylate Tablets, USP, 2.5 mg. The recall involves 100-count unit dose blisters (NDC 51079-450-20) and 30-count tablets per dosage card (NDC 51079-450-63). The affected lots are 3039792, 3037880, 3043938, 3036811, 3037514, 3039975, and 3042583.
The recall was initiated because the pharmaceuticals were produced and distributed with active ingredients that were not manufactured according to Good Manufacturing Practices (CGMP Deviations). The agency has classified this as a Class II recall.
The affected products were distributed nationwide, as well as in Puerto Rico and Guam. Consumers and healthcare providers should stop using the affected lots and contact their healthcare provider or pharmacist for guidance on alternative treatment options.
The recalled product
- Product
- Amlodipine Besylate Tablets, USP, 2.5 mg*, packaged in a)100-count (10 x 10) unit dose blisters per carton, NDC 51079-450-20 and b) 30-count tablets per dosage card in a carton, NDC 51079-450-63, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505; Package
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- Lot #: a) 3039792
- Exp 04/14
- 3037880
- Exp 01/14
- 3043938
- Exp 07/14
- b) 3036811
- Exp 10/13
- 3037514
- 3039975
- 3042583
Distribution
Part of a larger recall action
This product is one of 3 recalled by Mylan Institutional, Inc. (d.b.a. UDL Laboratories) under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
See all →- ModerateEsomeprazole Magnesium Delayed-Release Capsules Recalled for Failed Quality Specifications
FDA (Drugs) · 2022-05-18
- HighEsomeprazole magnesium delayed-release capsules recalled for impurity specification failure
FDA (Drugs) · 2022-05-18
- SevereMylan Recalls Alprazolam Tablets Due to Elevated Impurity Levels
FDA (Drugs) · 2019-03-27
- LowMylan Recalls Diltiazem HCl Extended-release Capsules Due to Impurities
FDA (Drugs) · 2018-08-29
- ModerateMylan Recalls Loxapine Capsules Due to Cross-Contamination Risk
FDA (Drugs) · 2018-05-30
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19